These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 26833058)

  • 1. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway.
    Hao J; Chen C; Huang K; Huang J; Li J; Liu P; Huang H
    Eur J Pharmacol; 2014 Dec; 745():152-65. PubMed ID: 25310908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
    Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
    J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
    Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
    Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polydatin Improves Glucose and Lipid Metabolisms in Insulin-Resistant HepG2 Cells through the AMPK Pathway.
    Hao J; Huang K; Chen C; Liang Y; Wang Y; Zhang X; Huang H
    Biol Pharm Bull; 2018; 41(6):891-898. PubMed ID: 29863077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.